<p>北卡罗来纳州夏洛特，2025 年 12 月 23 日（GLOBE NEWSWIRE）——Prenetics Global Limited（纳斯达克：PRE）（“Prenetics” 或 “公司”），一家领先的健康科学公司及 IM8 高端健康与长寿品牌的母公司，今天宣布已与持有约 83.4% 已发行 A 类和 B 类认股权证的持有人达成认股权证交换协议，协议需满足惯常的成交条件，旨在简化公司的资本结构并大幅减少未来潜在的稀释。</p>
<p>该认股权证交换计划是基于投资者反馈并在与几位公司最大机构股东的讨论后制定的，这些股东对将传统认股权证工具整合为更清晰的资本结构表示了强烈支持。</p>
<p><strong>背景与参与</strong></p>
<p>在公司 2025 年 10 月的融资中，发行了 2,722,642 股 A 类普通股，每股 A 类普通股对应发行一份 A 类认股权证和一份 B 类认股权证，共计 5,445,284 份认股权证。</p>
<p>截至本公告之日，公司已签署的交换协议涵盖了 5,445,284 份 A 类和 B 类认股权证中的 4,539,722 份，参与比例约为 83.4%。</p>
<p><strong>认股权证交换摘要</strong></p>
<p>根据交换协议：</p>
<ul>
<li>一（1）份 A 类认股权证和一（1）份 B 类认股权证，行使价格分别为 24.12 美元和 32.16 美元，每份认股权证的有效期为五年，已被交换为</li>
<li>一（1）份新的 C 类认股权证，其：
<ul>
<li>A 类普通股的行使价格为 18.00 美元，</li>
<li>自 F-3 表格注册声明生效之日起有效期为两年，该注册声明用于注册因行使 C 类认股权证而可发行的股份的转售，</li>
<li>具有标准的强制赎回（回购）条款。</li>
</ul>
</li>
</ul>
<p>公司仅在 F-3 表格注册声明生效后，且仅在公司 A 类普通股连续十（10）个交易日的交易价格达到或超过行使价格的 120%（即 21.60 美元）时，方可行使其强制赎回权。</p>
<p>认股权证持有人自愿参与此次交换，所有符合条件的认股权证持有人均获得相同的条款。</p>
<p><strong>对资本结构的影响</strong></p>
<p>根据交换协议，预计公司约 4.54 百万份已发行的 A 类和 B 类认股权证将被交换为约 2.27 百万份 C 类认股权证。</p>
<p>在此次交换后，预计 A 类、B 类和 C 类认股权证的总数将约为 3.18 百万份，较 2025 年 10 月融资轮中发行的 A 类和 B 类认股权证数量减少约 42.0%，如果所有 A 类和 B 类认股权证持有人全部参与，减少幅度可达 50%。</p>
<p>公司认为，这一减少显著改善了其长期稀释状况，降低了认股权证的过剩，并增强了其普通股的投资吸引力。公司并未因任何融资交易而进行此次认股权证交换，且在可预见的未来没有进行任何股权或股权相关融资的计划。</p>
<p><strong>战略理由与好处</strong></p>
<p>公司认为，此次认股权证交换为公司及其股东带来了几项重要好处，包括：</p>
<ul>
<li>A 类和 B 类认股权证数量减少高达 50%，显著降低长期稀释风险</li>
<li>大幅消除两类深度虚值的传统认股权证，减少公司股份因 A 类和 B 类认股权证而产生的过剩，降低幅度可达 50%</li>
<li>简化为单一统一的认股权证类别，提高透明度和机构投资吸引力</li>
<li>与股东的改善对齐，提供更现实和可实现的认股权证赎回路径</li>
</ul>
<p>公司指出，其最大的机构投资者均参与了此次交换，反映出对修订结构及其长期利益的强烈信心。</p>
<p><strong>关于 Prenetics</strong></p>
<p>Prenetics（纳斯达克：PRE）是一家领先的健康科学公司，通过 IM8——其与大卫·贝克汉姆共同创立的旗舰消费品牌，重新定义健康与长寿的未来，并由世界排名第一的网球选手阿丽娜·萨巴伦卡支持。IM8 在补充剂行业历史上实现了最快的增长轨迹，在推出 11 个月内达到了超过 1 亿美元的年经常性收入，甚至超过了领先的人工智能初创公司。</p>
<p><strong>关于 IM8</strong></p>
<p>IM8 是高端核心营养的巅峰之作，由大卫·贝克汉姆作为共同创始人，与一支由医疗专业人士、学术界和太空科学领域的精英科学家组成的团队合作而成。IM8 结合尖端科学与自然中最有效的成分，提供一种全面的、科学支持的健康方法，使您能够过上最充实的生活。IM8 的旗舰产品 “每日终极必需品” 是一种全能粉末补充剂，旨在替代 16 种不同的补充剂，口感美味，并获得 NSF 运动认证，非转基因，素食，无常见过敏原，不含人工香料、色素或甜味剂。IM8 是 Prenetics（纳斯达克：PRE）的子公司，致力于推动消费者健康。欲了解更多关于 IM8 的信息，请访问 www.IM8health.com。</p>
<p><strong>投资者关系联系方式：</strong></p>
<p>investors@prenetics.com</p>
<p>PRE@mzgroup.us</p>
<p>Angela Cheung</p>
<p>投资者关系 / 企业融资</p>
<p>angela.hm.cheung@prenetics.com</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含前瞻性声明。这些声明是在 1995 年美国《私人证券诉讼改革法案》的 “安全港” 条款下作出的。非历史事实的声明，包括关于公司的目标、指标、预测、展望、信念、期望、战略、计划、管理层对公司未来运营的目标以及增长机会的声明，均为前瞻性声明。我们的指引（包括认股权证结构、数字和时间表）反映了管理层截至本发布日的当前估计和假设，受到重大风险和不确定性的影响，并不保证未来的表现。实际结果可能会有重大差异。在某些情况下，前瞻性声明可以通过 “可能”、“将”、“期望”、“预期”、“目标”、“旨在”、“估计”、“打算”、“计划”、“相信”、“潜在”、“继续”、“可能会”、“指引”、“展望”、“预测” 或其他类似表达来识别。前瞻性声明基于估计和预测，反映了公司的观点、假设、期望和意见，这些都涉及固有的风险和不确定性，因此不应被视为未来结果的必然指示。多种因素可能导致实际结果与任何前瞻性声明中包含的内容有重大差异，包括但不限于超出公司控制的因素，这些因素阻止了交换协议的完成和最终实现。除了上述因素外，您还应仔细考虑公司最近注册声明和其中的招股说明书以及公司不时向美国证券交易委员会提交的其他文件中描述的其他风险和不确定性。除非另有说明，本新闻稿中提供的所有信息均截至本新闻稿日期，公司不承担更新该信息的任何义务，除非适用法律要求。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE5qVTVOaU0zTXpNME56VXpJekl5TWpRd09UWT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE5qVTVOaU0zTXpNME56VXpJekl5TWpRd09UWT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/M2NmZTY2NDItYTA2OC00OWZlLTg2MzMtNmM4OTM1YjhhMzQxLTEyMzU2NDktMjAyNS0xMi0yMy1lbg==/tiny/Prenetics-Global-Limited.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/M2NmZTY2NDItYTA2OC00OWZlLTg2MzMtNmM4OTM1YjhhMzQxLTEyMzU2NDktMjAyNS0xMi0yMy1lbg==/tiny/Prenetics-Global-Limited.png"/></p>

<p>Prenetics Global Limited 宣布与持有 83.4% A 类和 B 类认股权证的投资者达成认股权证交换协议，旨在简化其资本结构并减少未来的稀释。此次交换涉及将 A 类和 B 类认股权证换为新的 C 类认股权证，后者具有更低的行使价格和两年的有效期。此举预计将使未到期的认股权证减少多达 50%，改善长期稀释状况并增强股票的投资吸引力。此次交换反映了投资者对 Prenetics 修订结构的强烈支持和信心</p>

<p>CHARLOTTE, N.C., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced that it has entered into warrant exchange agreements, subject to customary closing conditions, with holders representing approximately 83.4% of its outstanding Class A and Class B warrants, pursuant to a voluntary warrant exchange program designed to simplify the Company’s capital structure and materially reduce potential future dilution.</p>
<div class="lb-trans"><p>北卡罗来纳州夏洛特，2025 年 12 月 23 日（GLOBE NEWSWIRE）——Prenetics Global Limited（纳斯达克：PRE）（“Prenetics” 或 “公司”），一家领先的健康科学公司及 IM8 高端健康与长寿品牌的母公司，今天宣布已与持有约 83.4% 已发行 A 类和 B 类认股权证的持有人达成认股权证交换协议，协议需满足惯常的成交条件，旨在简化公司的资本结构并大幅减少未来潜在的稀释。</p>
</div><p>The warrant exchange program was developed based on investor feedback and following discussions with several of the Company’s largest institutional shareholders, who expressed strong support for consolidating legacy warrant instruments into a cleaner capital structure.</p>
<div class="lb-trans"><p>该认股权证交换计划是基于投资者反馈并在与几位公司最大机构股东的讨论后制定的，这些股东对将传统认股权证工具整合为更清晰的资本结构表示了强烈支持。</p>
</div><p><strong>Background and Participation</strong></p>
<div class="lb-trans"><p><strong>背景与参与</strong></p>
</div><p>In connection with the Company’s prior financing in October 2025, 2,722,642 Class A ordinary shares were issued, with one Class A warrant and one Class B warrant issued for each such Class A ordinary share, for a total of 5,445,284 warrants.</p>
<div class="lb-trans"><p>在公司 2025 年 10 月的融资中，发行了 2,722,642 股 A 类普通股，每股 A 类普通股对应发行一份 A 类认股权证和一份 B 类认股权证，共计 5,445,284 份认股权证。</p>
</div><p>As of the date of this announcement, the Company has entered into exchange agreements covering 4,539,722 of the 5,445,284 aggregate Class A and Class B warrants, representing approximately 83.4% participation.</p>
<div class="lb-trans"><p>截至本公告之日，公司已签署的交换协议涵盖了 5,445,284 份 A 类和 B 类认股权证中的 4,539,722 份，参与比例约为 83.4%。</p>
</div><p><strong>Summary of the Warrant Exchange</strong></p>
<div class="lb-trans"><p><strong>认股权证交换摘要</strong></p>
</div><p>Under the exchange agreements:</p>
<div class="lb-trans"><p>根据交换协议：</p>
</div><ul>
<li>One (1) Class A warrant and one (1) Class B warrant with exercise prices of $24.12 and $32.16, respectively, each with a five-year term have been exchanged for</li>
<li>One (1) new Class C warrant with:
<ul>
<li>an exercise price of $18.00 per Class A ordinary share,</li>
<li>a two-year term commencing upon the effectiveness of a registration statement on Form F-3 registering the resale of the shares issuable upon exercise of the Class C warrants, and</li>
<li>a standard forced-redemption (call) feature.</li>
</ul>
</li>
</ul>
<div class="lb-trans"><ul>
<li>一（1）份 A 类认股权证和一（1）份 B 类认股权证，行使价格分别为 24.12 美元和 32.16 美元，每份认股权证的有效期为五年，已被交换为</li>
<li>一（1）份新的 C 类认股权证，其：
<ul>
<li>A 类普通股的行使价格为 18.00 美元，</li>
<li>自 F-3 表格注册声明生效之日起有效期为两年，该注册声明用于注册因行使 C 类认股权证而可发行的股份的转售，</li>
<li>具有标准的强制赎回（回购）条款。</li>
</ul>
</li>
</ul>
</div><p>The Company may exercise its forced-redemption right only after the registration statement on Form F-3 registering the resale of the shares issuable upon exercise of the Class C warrants is declared effective and only if the Company’s Class A ordinary shares trade at or above 120% of the exercise price (i.e., $21.60) for ten (10) consecutive trading days.</p>
<div class="lb-trans"><p>公司仅在 F-3 表格注册声明生效后，且仅在公司 A 类普通股连续十（10）个交易日的交易价格达到或超过行使价格的 120%（即 21.60 美元）时，方可行使其强制赎回权。</p>
</div><p>Warrant holders participated in the exchange on a voluntary basis, and identical terms were offered to all eligible warrant holders.</p>
<div class="lb-trans"><p>认股权证持有人自愿参与此次交换，所有符合条件的认股权证持有人均获得相同的条款。</p>
</div><p><strong>Impact on Capital Structure</strong></p>
<div class="lb-trans"><p><strong>对资本结构的影响</strong></p>
</div><p>Based on the exchange agreements, a total of approximately 4.54 million in aggregate of the Company’s outstanding Class A warrants and Class B warrants is expected to be exchanged for approximately 2.27 million Class C warrants.</p>
<div class="lb-trans"><p>根据交换协议，预计公司约 4.54 百万份已发行的 A 类和 B 类认股权证将被交换为约 2.27 百万份 C 类认股权证。</p>
</div><p>After such exchange, the total number of outstanding Class A warrants, Class B warrants and Class C warrants is expected to be approximately 3.18 million in aggregate, representing a reduction of approximately 42.0% from the number of Class A and Class B warrants issued in the October 2025 financing round, and further up to 50% assuming participation in full by all holders of Class A warrants and Class B warrants.</p>
<div class="lb-trans"><p>在此次交换后，预计 A 类、B 类和 C 类认股权证的总数将约为 3.18 百万份，较 2025 年 10 月融资轮中发行的 A 类和 B 类认股权证数量减少约 42.0%，如果所有 A 类和 B 类认股权证持有人全部参与，减少幅度可达 50%。</p>
</div><p>The Company believes this reduction materially improves its long-term dilution profile, reduces warrant overhang, and enhances the investability of its ordinary shares. The Company is not undertaking this warrant exchange in connection with any financing transaction and has no plans to conduct any equity or equity-linked capital raise in the foreseeable future.</p>
<div class="lb-trans"><p>公司认为，这一减少显著改善了其长期稀释状况，降低了认股权证的过剩，并增强了其普通股的投资吸引力。公司并未因任何融资交易而进行此次认股权证交换，且在可预见的未来没有进行任何股权或股权相关融资的计划。</p>
</div><p><strong>Strategic Rationale and Benefits</strong></p>
<div class="lb-trans"><p><strong>战略理由与好处</strong></p>
</div><p>The Company believes this warrant exchange delivers several meaningful benefits to the Company and its shareholders, including:</p>
<div class="lb-trans"><p>公司认为，此次认股权证交换为公司及其股东带来了几项重要好处，包括：</p>
</div><ul>
<li>Up to 50% reduction from the number of outstanding Class A warrants and Class B warrants, materially lowering long-term dilution risk</li>
<li>Substantial elimination of two deep out-of-the-money legacy classes of warrants, reducing up to 50% of the overhang on the Company’s shares that resulted from the Class A warrants and Class B warrants</li>
<li>Simplification in favor of a single, unified class of warrants, improving transparency and institutional investability</li>
<li>Improved alignment with shareholders, by providing a more realistic and attainable path to warrant redemption</li>
</ul>
<div class="lb-trans"><ul>
<li>A 类和 B 类认股权证数量减少高达 50%，显著降低长期稀释风险</li>
<li>大幅消除两类深度虚值的传统认股权证，减少公司股份因 A 类和 B 类认股权证而产生的过剩，降低幅度可达 50%</li>
<li>简化为单一统一的认股权证类别，提高透明度和机构投资吸引力</li>
<li>与股东的改善对齐，提供更现实和可实现的认股权证赎回路径</li>
</ul>
</div><p>The Company noted that its largest institutional investors, each with significant long-term investments, have participated in the exchange, reflecting strong confidence in the revised structure and its long-term benefits.</p>
<div class="lb-trans"><p>公司指出，其最大的机构投资者均参与了此次交换，反映出对修订结构及其长期利益的强烈信心。</p>
</div><p><strong>About Prenetics</strong></p>
<div class="lb-trans"><p><strong>关于 Prenetics</strong></p>
</div><p>Prenetics (NASDAQ: PRE) is a leading health sciences company redefining the future of health and longevity through IM8 — its flagship consumer brand co-founded with David Beckham and championed by World No. 1 tennis player Aryna Sabalenka. IM8 has achieved the fastest growth trajectory in supplement industry history, reaching $100 million+ in ARR within 11 months of launch, outpacing even leading AI startups.</p>
<div class="lb-trans"><p>Prenetics（纳斯达克：PRE）是一家领先的健康科学公司，通过 IM8——其与大卫·贝克汉姆共同创立的旗舰消费品牌，重新定义健康与长寿的未来，并由世界排名第一的网球选手阿丽娜·萨巴伦卡支持。IM8 在补充剂行业历史上实现了最快的增长轨迹，在推出 11 个月内达到了超过 1 亿美元的年经常性收入，甚至超过了领先的人工智能初创公司。</p>
</div><p><strong>About IM8</strong></p>
<div class="lb-trans"><p><strong>关于 IM8</strong></p>
</div><p>IM8 is the pinnacle of premium core nutrition, born from a collaboration between David Beckham as a co-founding partner, and an elite team of scientists spanning medical professionals, academia and space science. Combining cutting-edge science with nature’s most potent ingredients, IM8 delivers a holistic, science-backed approach to health, empowering you to live your most vibrant life. IM8’s flagship product, Daily Ultimate Essentials is an all-in-one powder supplement engineered to replace 16 different supplements in a delicious drink and is NSF Certified for Sport, non-GMO, vegan, free from common allergens, and contains no artificial flavors, colors or sweeteners. IM8 is a subsidiary of Prenetics (NASDAQ: PRE), a leading global health sciences company dedicated to advancing consumer health. To learn more about IM8, please visit www.IM8health.com.</p>
<div class="lb-trans"><p>IM8 是高端核心营养的巅峰之作，由大卫·贝克汉姆作为共同创始人，与一支由医疗专业人士、学术界和太空科学领域的精英科学家组成的团队合作而成。IM8 结合尖端科学与自然中最有效的成分，提供一种全面的、科学支持的健康方法，使您能够过上最充实的生活。IM8 的旗舰产品 “每日终极必需品” 是一种全能粉末补充剂，旨在替代 16 种不同的补充剂，口感美味，并获得 NSF 运动认证，非转基因，素食，无常见过敏原，不含人工香料、色素或甜味剂。IM8 是 Prenetics（纳斯达克：PRE）的子公司，致力于推动消费者健康。欲了解更多关于 IM8 的信息，请访问 www.IM8health.com。</p>
</div><p><strong>Investor Relations Contact:</strong></p>
<div class="lb-trans"><p><strong>投资者关系联系方式：</strong></p>
</div><p>investors@prenetics.com</p>
<div class="lb-trans"><p>investors@prenetics.com</p>
</div><p>PRE@mzgroup.us</p>
<div class="lb-trans"><p>PRE@mzgroup.us</p>
</div><p>Angela Cheung</p>
<div class="lb-trans"><p>Angela Cheung</p>
</div><p>Investor Relations / Corporate Finance</p>
<div class="lb-trans"><p>投资者关系 / 企业融资</p>
</div><p>angela.hm.cheung@prenetics.com</p>
<div class="lb-trans"><p>angela.hm.cheung@prenetics.com</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s goals, targets, projections, outlooks, beliefs, expectations, strategy, plans, objectives of management for future operations of the Company, and growth opportunities are forward-looking statements. Our guidance (including warrant structure, numbers and timeline) reflects management’s current estimates and assumptions as of the date of this release, is subject to significant risks and uncertainties, and is not a guarantee of future performance. Actual results may differ materially. In some cases, forward-looking statements can be identified by words or phrases such as “may,” “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to,” “guidance,” “outlook,” “forecast,” or other similar expressions. Forward-looking statements are based upon estimates and forecasts and reflect the views, assumptions, expectations, and opinions of the Company, which involve inherent risks and uncertainties, and therefore they should not be relied upon as being necessarily indicative of future results. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to factors beyond the Company’s control that prevent the closing and final consummation of the exchange agreements. In addition to the foregoing factors, you should also carefully consider the other risks and uncertainties described in the “Risk Factors” section of the Company’s most recent registration statement and the prospectus therein, and the other documents filed by the Company from time to time with the U.S. Securities and Exchange Commission. Unless otherwise specified, all information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.</p>
<div class="lb-trans"><p>本新闻稿包含前瞻性声明。这些声明是在 1995 年美国《私人证券诉讼改革法案》的 “安全港” 条款下作出的。非历史事实的声明，包括关于公司的目标、指标、预测、展望、信念、期望、战略、计划、管理层对公司未来运营的目标以及增长机会的声明，均为前瞻性声明。我们的指引（包括认股权证结构、数字和时间表）反映了管理层截至本发布日的当前估计和假设，受到重大风险和不确定性的影响，并不保证未来的表现。实际结果可能会有重大差异。在某些情况下，前瞻性声明可以通过 “可能”、“将”、“期望”、“预期”、“目标”、“旨在”、“估计”、“打算”、“计划”、“相信”、“潜在”、“继续”、“可能会”、“指引”、“展望”、“预测” 或其他类似表达来识别。前瞻性声明基于估计和预测，反映了公司的观点、假设、期望和意见，这些都涉及固有的风险和不确定性，因此不应被视为未来结果的必然指示。多种因素可能导致实际结果与任何前瞻性声明中包含的内容有重大差异，包括但不限于超出公司控制的因素，这些因素阻止了交换协议的完成和最终实现。除了上述因素外，您还应仔细考虑公司最近注册声明和其中的招股说明书以及公司不时向美国证券交易委员会提交的其他文件中描述的其他风险和不确定性。除非另有说明，本新闻稿中提供的所有信息均截至本新闻稿日期，公司不承担更新该信息的任何义务，除非适用法律要求。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE5qVTVOaU0zTXpNME56VXpJekl5TWpRd09UWT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYxNjU5NiM3MzM0NzUzIzIyMjQwOTY="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/M2NmZTY2NDItYTA2OC00OWZlLTg2MzMtNmM4OTM1YjhhMzQxLTEyMzU2NDktMjAyNS0xMi0yMy1lbg==/tiny/Prenetics-Global-Limited.png" alt="" original-src="https://ml.globenewswire.com/media/M2NmZTY2NDItYTA2OC00OWZlLTg2MzMtNmM4OTM1YjhhMzQxLTEyMzU2NDktMjAyNS0xMi0yMy1lbg==/tiny/Prenetics-Global-Limited.png"/></p>

Prenetics 与认股权证持有人签署交换协议，以加强其资本结构 | PRE 股票新闻